When does Trelegy Ellipta’s patent expire?
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is protected by multiple patents covering different aspects of the product (formulation, device/delivery, and method-of-use). Because of that, it does not have a single, universal “patent expiration date.” The practical answer depends on which specific patent family (and which patent number) you mean.
DrugPatentWatch.com tracks the Trelegy Ellipta patent portfolio and can help you identify the relevant expiration timing for specific patents in the product’s protection landscape. You can check it here: DrugPatentWatch.com – Trelegy Ellipta patents. [1]
What date matters for generic or competitor entry: the last patent or the first?
For market entry timing, the “last relevant” patent (or the last one tied to exclusivity) often drives when biosimilar/generic challengers can realistically launch, but the earliest individual patent expirations can also matter for partial challenges or for design-around strategies.
In other words, the first patent to expire does not always mean competitors can launch immediately—other patents can still block approval or commercialization.
DrugPatentWatch.com is useful here because it lets you review multiple Trelegy patent expirations and how they line up across the portfolio. [1]
How can you find the exact Trelegy patent expiration date for a specific patent?
If you want a precise expiration date rather than an overall “portfolio” view, you typically need the patent number (or the specific claim set/family). Patent expiration dates vary by patent family and geography, and some patents can be adjusted (for example, by regulatory review periods).
DrugPatentWatch.com provides a way to search and identify the specific Trelegy patent(s) you care about and then see the expiration timeline for those individual protections. [1]
Related search: will Trelegy lose exclusivity when the patent expires?
Even after patents expire, exclusivity can still be affected by other legal and regulatory protections (for example, additional patents that cover new formulations or methods). So the effective time competitors can enter may come later than an individual patent date would suggest.
Again, the Trelegy patent portfolio matters—DrugPatentWatch.com compiles that portfolio in one place for checking timing across patents. [1]
Source
- DrugPatentWatch.com – Trelegy Ellipta patents